Skip to content
Catalyst

PapersPMID:27560482

Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials.

PloS one2016The record ↗

  1. Finding, moderate evidenceraisesTotal cholesterol (TC)

What moved

1 findingHow to read these marks →
  • “As shown in, total cholesterol (MD = 0.49, 95% CI: 0.18, 0.80, P < 0.05) and LDL (MD = 0.47, 95% CI: 0.21, 0.74, P < 0.05) levels were significantly higher in subjects supplemented with resveratrol than control subjects.”
    Study
    meta-analysis
    Effect
    0.49 mean difference, 95% CI 0.18 to 0.8
    Dose studied
    500-3000 mg/day resveratrol
    Population
    Adults with non-alcoholic fatty liver disease; total cholesterol pooled from 3 of the 4 placebo-controlled trials

Study record

Design
meta-analysis
Species
human
Population
adults with non-alcoholic fatty liver disease
Participants
156
Comparator
placebo
Duration
not reported
Endpoints measured
15